Given the
interrelatedness of this collection to the information collected in
0910-0116, FDA should evaluate whether this collection should be
merged with 0910-0116. In particular, FDA should evaluate whether
there are opportunities to reduce burden and/or increase the
practical utility of both sets of information collected (e.g.,
finalizing the guidance document recognizing the acceptability of
"DHQ documents" for donor screening). Thus, we will approve this
collection which merges the previously approved 0910-0472 and
0910-0474, until 11/30/2005 (the expiration date of
0910-0116).
Inventory as of this Action
Requested
Previously Approved
11/30/2005
11/30/2005
09/30/2004
479,758
0
29,356
145,270
0
3,125
0
0
0
This collection of information
requirement helps prevent the transmission of communicable diseases
by testing human blood donors for evidence of infection due to
communicable disease agents and by donor notification. Respondents
to this collection of information are Whole Blood and Source Plasma
establishments that collect blood and blood components, including
Source Plasma and Source Leukocytes.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.